Hedge funds investors control 50% of TScan Therapeutics, Inc. (NASDAQ:TCRX) and were rewarded last week after stock increased 16% [Yahoo! Finance]
TScan Therapeutics, Inc. (TCRX)
Company Research
Source: Yahoo! Finance
50% of the business is held by the top 5 shareholders Using data from analyst forecasts alongside ownership research, one can better assess the future performance of a company If you want to know who really controls TScan Therapeutics, Inc. ( NASDAQ:TCRX ), then you'll have to look at the makeup of its share registry. We can see that hedge funds own the lion's share in the company with 50% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company. Last week's 16% gain means that hedge funds investors were on the positive end of the spectrum even as the company has shown strong longer-term trends. The one-year return on investment is currently 229% and last week's gain would have been more than welcomed. Let's take a closer look to see what the different types of shareholders can tell us about TScan Therapeutics. Check out our latest analysis for TScan Therapeutics What Does The Institutional Ownership Tell Us Ab
Show less
Read more
Impact Snapshot
Event Time:
TCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TCRX alerts
High impacting TScan Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TCRX
News
- TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting [Yahoo! Finance]Yahoo! Finance
- TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual MeetingGlobeNewswire
- TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswire
- TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $10.00 price target on the stock.MarketBeat
- TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting [Yahoo! Finance]Yahoo! Finance
TCRX
Earnings
- 11/9/23 - Beat
TCRX
Sec Filings
- 4/23/24 - Form SC
- 4/23/24 - Form 4
- 4/23/24 - Form 4
- TCRX's page on the SEC website